Epcoritamab and Pola-R-CHP combination in newly diagnosed DLBCL showed high ORR (100%) and CR (97%) in all subgroups of DLBCL with no high-grade CRS [19]. Here, POLA1 is linked to diffuse large B-cell lymphoma.